Skip to main content
OpenTrials
Completed

NCT Number: NCT02810080

FiO2 Closed Loop Control Ventilation

A randomized, multi-center trial involving critically-ill patients comparing conventional, manual control of inspired oxygen (FiO2) within a target range, with a computer-controlled, closed-loop FiO2 delivery using a continuous ventilator.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Primary location

Regions Hospital

Saint Paul, Minnesota, 55101, United States

About this study

The trial will use a proportional-integral-derivative (PID) type controller for automatic adjustment of FiO2 to maintain the SpO2 within a target range, based on continuous use of pulse oximetry. Intubated subjects will be randomized to either manual control of FiO2 or closed-loop control of FiO2, during a 12-hour period. The PCLC is designed to respond to acute hypoxemia (SpO2 <88%) within seconds while preventing hypoxemia and minimizing exposure to excessive inspired oxygen levels.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject's legally authorized representative will provide signed and dated informed consent.
  • Age 18 - 65, inclusive.
  • Admission to a surgical or neurosurgical intensive care unit following traumatic injury or acute surgical illness
  • Requirement for endotracheal intubation
  • Requirement for mechanical ventilation
  • Patient is currently receiving inspired oxygen concentration (FiO2) >=40%

Exclusion criteria

  • Age under 18 or over 65
  • Isolated or severe head injury (Glasgow Coma Scale = 6 or less) with expected survival less than 24 hours
  • Brain death
  • Anticipated survival less than 48 hours
  • Pregnant female
  • Patient in whom a pulse oximeter cannot detect a reliable signal due to hypotension, hypothermia, or other injury
  • Known carbon monoxide poisoning
  • Uncontrolled diabetic
  • Patient who is unable to maintain SpO2 level of 88% at an FiO2 of 100% due to their medical condition. (NOTE: Being in the trial would impose no additional risk to a patient who presents with this condition however, data from a patient presenting with this pathophysiology would not provide insight into the performance of the controller as it would simply maintain that patient on an FiO2 of 100%.)
  • Patient with chronic hypercarbia.
  • Patient where a physician believes that FiO2 PCLC could be detrimental to the management of the patient.
  • Prisoner
  • SpO2 to SaO2 difference >4%
  • Patient with core temperature <35 C

Treatment and study plan

Closed Loop Control Ventilation

Device

Closed loop control ventilation using ZOLL 731 ventilator with physiologic closed-loop control software

Manual Control Ventilation

Device

Manual control ventilation using ZOLL 731 ventilator

Primary outcomes

  1. Relative Duration With Oxygen Saturation (SpO2) Within Target Range [Time Frame: 12 Hours]

    Time frame: 12 hours

    Relative duration is (time within SpO2 target of 92-96%)/12 hours where higher value demonstrates better ability of FiO2 control method to maintain appropriate oxygen saturation.

    Relative time the patient's SpO2 was maintained within target over the 12 hours on the study device, calculated as total time each patient had SpO2 within the 92 - 96% range divided by 12 hours with arcsin square root transformation

  2. Number of Participants With SpO2 Less Than 88% at Anytime While on Study Device

    Time frame: 24 hours after intervention

    Number of participants with SpO2 less than 88% at anytime while on study device

Secondary outcomes

  1. Relative Duration of Time With SpO2 92 to 96% When FiO2 is Greater Than 21% and SpO2 is Greater Than or Equal to 92% When Fi02 "Relative Duration With Oxygen Saturation (SpO2) Within Target Range [Time Frame: 12 Hours]

    Time frame: 12 hours

    Relative duration is (time within SpO2 target of either a) 92-96% when FiO2 is greater than 21% or b) greater than or equal to 92% when FiO2 equals 21%)/12 hours where higher value demonstrates better ability of FiO2 control method to maintain appropriate oxygen saturation.

    Relative time the patient's SpO2 was maintained within target over the 12 hours on the study device, calculated as total time each patient had SpO2 within the range divided by 12 hours with arcsin square root transformation

Sponsors and collaborators

Lead sponsor

Zoll Medical Corporation

Industry

Collaborators

  • United States Air Force

Registry information

Official study title

FiO2 Closed Loop Control Using the ZOLL 731 Series Ventilator

Acronym: CLC

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Jun 22, 2016
Registry last updated
Aug 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.